Urological cancer: Abiraterone and its place in the treatment of metastatic CRPC

Nature Reviews Clinical Oncology

Volumn 10, Issue 1, 2013, Pages 6-8

  Sartor, Oliver ^a   Pal, Sumanta K ^b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ENZALUTAMIDE; PLACEBO; PREDNISONE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; DOCETAXEL; TAXOID;

ANDROGEN DEPRIVATION THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; HUMAN; MONOTHERAPY; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME; ARTICLE; CASTRATION; MALE; METASTASIS; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE TUMOR;

ANDROSTENOLS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASTRATION; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MALE; NEOPLASM METASTASIS; PREDNISONE; PROSTATIC NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 84871624121     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.202     Document Type: Note

References (10)

1. Fizazi, K. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 13, 983-992 (2012).
2. Scher, H. I. et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 26, 1148-1159 (2008).
3. Attard, G. et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 27, 3742-3748 (2009).
4. Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187-1197 (2012).
5. Ryan, C. J. et al. Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) [abstract]. J. Clin. Oncol. 30 (Suppl.), LBA4518 (2012).
6. Parker, C. et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases [abstract]. J. Clin. Oncol. 30 (Suppl. 5), a8 (2012).
7. Pal, S. K., Lewis, B. & Sartor, O. Management of docetaxel failures in metastatic castrate-resistant prostate cancer. Urol. Clin. North Am. 39, 583-591 (2012).
8. Mezynski, J. et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann. Oncol. 23, 2943-2947 (2012).
9. Albiges, L. et al. Response to cabazitaxel in the post-chemotherapy setting in CRPC patients previously treated with docetaxel and abiraterone acetate [abstract]. Ann. Oncol. 23, a951 (2012).
10. Bolla, M. et al. Duration of androgen suppression in the treatment of prostate cancer. N. Engl. J. Med. 360, 2516-2527 (2009).